Great Point Partners’s Nektar Therapeutics NKTR Stock Holding History

Great Point Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.8M	Buy	316,453 +105,721	+50%	+$6.02M	5.23%	6
2025 Q4	$8.91M	Sell	210,732 -89,268	-30%	-$5M	2.89%	15
2025 Q3	$17.1M	Buy	+300,000	New	+$9.93M	7.04%	3
2022 Q4	–	Sell	-29,855	Closed	-$1.43M	–	50
2022 Q3	$1.43M	Sell	29,855 -180,145	-86%	-$10.7M	0.35%	37
2022 Q2	$12M	Buy	+210,000	New	+$13.2M	2.87%	15
2021 Q4	–	Sell	-33,646	Closed	-$7.3M	–	43
2021 Q3	$9.06M	Buy	+33,646	New	+$8.09M	2.11%	21
2019 Q4	–	Sell	-141,667	Closed	-$38.7M	–	43
2019 Q3	$38.7M	Buy	+141,667	New	+$52M	3.56%	11

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Point Partners's NKTR Position: Q1 2026 in Review

Great Point Partners increased its Nektar Therapeutics (NKTR) stake by 50% in Q1 2026, buying an estimated $6.02M and bringing the position to 316,453 shares worth $22.8M. The position accounts for 5.23% of the portfolio, ranked #6.

Great Point Partners first reported a position in NKTR in Q3 2019 and has held it in 7 quarters since. The position peaked at $38.7M in Q3 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Great Point Partners held 316,453 shares of Nektar Therapeutics worth $22.8M as of Q1 2026.
Great Point Partners bought 105,721 Nektar Therapeutics shares in Q1 2026, an estimated $6.02M.
Nektar Therapeutics made up 5.23% of Great Point Partners's portfolio in Q1 2026, its #6 holding.
Great Point Partners first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 7 quarters since.
Great Point Partners's Nektar Therapeutics position peaked at $38.7M in Q3 2019.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.